Gene therapy Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
22:50
Jan 07
Jan 07
Gene therapy is next major theme
The speaker expects gene therapy to become the main 2026 pharma/biotech theme, with the weight shifting away from obesity. She cites improving gene-therapy data in obesity, including good safety, fat loss without muscle loss, and durable effects, and notes that Lilly has invested in Korean gene-therapy companies. Investors should study gene-therapy names throughout the year.
HIGH
About Gene therapy Investor Commentary
Across the available history and selected sources, Buzzberg tracks Gene therapy across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Kim Seon-ah.